Guide to the correct usage and dosage of Gosatuzumab/Todavir
Gosatuzumab/Trodelvy (Trodelvy) is an antibody-drug conjugate (ADC), mainly used to treat advanced or metastatic solid tumors such as breast cancer and urothelial cancer. To ensure efficacy and reduce side effects, correct usage and dosage are the key to successful treatment.
First of all, the drug is administered by intravenous injection. It is recommended that 21 days be a complete treatment cycle, with one injection on the 1st and 8th day. Each dose is 10 mg/kg based on the patient's weight, and the injection time should be controlled between 1 and 3 hours. It is recommended that the first infusion be administered slowly and with close observation after injection to reduce the risk of allergic or infusion reactions.

Adequate anti-nausea pretreatment is required before injection, including the use of 5-HT3 antagonists, steroids and NK1 receptor antagonists to reduce common side effects of nausea and vomiting. Patients with a history of severe infusion reactions should also be premedicated with antihistamines.
The course of treatment should be continued until the disease progresses significantly or intolerable adverse reactions occur. If serious toxic reactions occur during treatment, such as neutropenia or severe diarrhea, the administration needs to be temporarily interrupted or the dose adjusted. After recovery, clinical judgment will be used to decide whether to continue treatment.
In addition, blood routine, liver and kidney function and weight changes should be closely monitored during treatment, and attention should be paid to whether the patient hasUGT1A1 gene polymorphism, because this may affect drug metabolism and increase the risk of toxicity. Patients should also strictly follow their doctor's instructions and avoid changing the dosage or frequency on their own.
In short, the use of gosatuzumab must be based on standardized dose management, adequate side effect prevention measures, and strict treatment monitoring.
It is conducted under the guidance of a professional medical team to maximize the treatment effect and safety.
Reference materials:https://www.trodelvy.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)